UPSTREAM BIO, INC. (UPB) Operating Margin
- Operating margin · 12 months: Value -5382.65%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -5382.65% | Operating income / revenue. Period ending 2026-06-30. $-169.98M ÷ $3.16M × 100 ≈ -5382.65% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -169.98M USD | Operating Income (Loss) |
| Revenue | 3.16M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 145.80M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-169.98M | $3.16M | (m) | $145.80M | (m) | -5382.65% |
| 2026-03-31 | $-171.96M | $3.32M | (m) | $147.57M | (m) | -5176.49% |
| 2025-12-31 | $-160.36M | $2.85M | (m) | $136.81M | (m) | -5618.82% |
| 2025-09-30 | $-140.51M | $2.80M | (m) | $118.41M | (m) | -5020.08% |
| 2025-06-30 | $-121.57M | $2.72M | (m) | $100.87M | (m) | -4464.60% |
| 2025-03-31 | $-94.76M | $2.30M | (m) | $77.07M | (m) | -4127.35% |
| 2024-12-31 | $-77.76M | $2.37M | (m) | $62.97M | (m) | -3281.18% |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $-40.11M | $2.38M | (m) | $31.80M | (m) | -1685.46% |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |